Activities
The Transformation of AML Therapy: Updates in Front-Line and Maintenance Therapies and Considerations for Older Patients
0290-0000-21-179-H01-P
This activity will focus on many novel agents used in the treatment of AML, including targeted agents and the role of hypomethylating agents in maintenance therapy.
1.00
BTK Inhibitors in B-Cell Malignancies: Implementing Digital Technology to Optimize Outcomes
0290-0000-21-180-H01-P
This activity will review the clinical data for the use of BTK inhibitors in the management of B-cell malignancies. Potential medication-associated adverse effects will be discussed, with an emphasis on cardiac events.
1.00
Interviewing the Experts in Alzheimer Disease: A Continuation of Specialist Opinion and Data
0290-0000-21-161-H01-P
This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for diagnosis and evaluation of AD and related dementias are incorporated into institutional management strategies.
1.50
Optimizing Proteasome Inhibitor Treatment in Multiple Myeloma: The Role of the Pharmacist
0290-0000-21-178-H01-P
This activity will review the place in therapy of PIs for MM, as well as the clinical data supporting their use.
1.00